Orthogonal ring-closing alkyne and olefin metathesis for the synthesis of small GTPase-targeting bicyclic peptides

Nature Communications

Volumn 7, Issue , 2016, Pages

  Cromm, Philipp M ^a,b   Schaubach, Sebastian ^b,c   Spiegel, Jochen ^a,b   Fürstner, Alois ^b,c   Grossmann, Tom N ^b,d,e   Waldmann, Herbert ^a,b  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG   (Germany)

^d CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKENE; ALKYNE; CYCLOPEPTIDE; HYDROLASE INHIBITOR; MACROCYCLIC COMPOUND; PROTEIN RAB8; RAB PROTEIN; UNCLASSIFIED DRUG; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN BINDING; RAB8A PROTEIN, HUMAN;

ENZYME ACTIVITY; GENE EXPRESSION; GEOMETRY; INHIBITOR; LIGAND; PEPTIDE; PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ONE POT SYNTHESIS; PEPTIDE SYNTHESIS; RING CLOSING METATHESIS; RING CLOSING OLEFIN ALKYNE METATHESIS; SOLID PHASE SYNTHESIS; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; SYNTHESIS;

ALKENES; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MONOMERIC GTP-BINDING PROTEINS; PEPTIDES, CYCLIC; PROTEIN BINDING; RAB GTP-BINDING PROTEINS;

EID: 84964296830     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11300     Document Type: Article

References (64)

1. Bock, J. E., Gavenonis, J. & Kritzer, J. A. Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints. ACS Chem. Biol. 8, 488-499 (2013).
2. Pelay-Gimeno, M., Glas, A., Koch, O. & Grossmann, T. N. Structure-based design of inhibitors of protein-protein interactions: mimicking peptide binding epitopes. Angew. Chem. Int. Ed. 54, 8896-8927 (2015).
3. Hill, T. A., Shepherd, N. E., Diness, F. & Fairlie, D. P. Constraining cyclic peptides to mimic protein structure motifs. Angew. Chem. Int. Ed. 53, 13020-13041 (2014).
4. Mas-Moruno, C., Rechenmacher, F. & Kessler, H. Cilengitide: the first anti-angiogenic small molecule drug candidate. design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 10, 753-768 (2010).
5. Srinivas, N. et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327, 1010-1013 (2010).
6. Leshchiner, E. S. et al. Direct inhibition of oncogenic KRAS by hydrocarbonstapled SOS1 helices. Proc. Natl Acad. Sci. USA 112, 1761-1766 (2015).
7. Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188 (2009).
8. Patgiri, A., Yadav, K. K., Arora, P. S. & Bar-Sagi, D. An orthosteric inhibitor of the Ras-Sos interaction. Nat. Chem. Biol. 7, 585-587 (2011).
9. Grossmann, T. N. et al. Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin. Proc. Natl Acad. Sci. USA 109, 17942-17947 (2012).
10. Upadhyaya, P. et al. Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides. Angew. Chem. Int. Ed. 54, 7602-7606 (2015).
11. Giordanetto, F. & Kihlberg, J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 57, 278-295 (2014).
12. Spiegel, J. et al. Direct targeting of Rab-GTPase-effector interactions. Angew. Chem. Int. Ed. 53, 2498-2503 (2014).
13. Northfield, S. E. et al. Disulfide-rich macrocyclic peptides as templates in drug design. Eur. J. Med. Chem. 77, 248-257 (2014).
14. Poth, A. G., Chan, L. Y. & Craik, D. J. Cyclotides as grafting frameworks for protein engineering and drug design applications. Biopolymers 100, 480-491 (2013).
15. Heinis, C., Rutherford, T., Freund, S. & Winter, G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat. Chem. Biol. 5, 502-507 (2009).
16. Baeriswyl, V. & Heinis, C. Polycyclic peptide therapeutics. Chem. Med. Chem. 8, 377-384 (2013).
17. White, C. J. & Yudin, A. K. Contemporary strategies for peptide macrocyclization. Nat. Chem. 3, 509-524 (2011).
18. Montalbetti, C. A. & Falque, V. Amide bond formation and peptide coupling. Tetrahedron 61, 10827-10852 (2005).
19. Góngora-Benítez, M., Tulla-Puche, J. & Albericio, F. Multifaceted roles of disulfide bonds. peptides as therapeutics. Chem. Rev. 114, 901-926 (2014).
20. Assem, N., Ferreira, D. J., Wolan, D. W. & Dawson, P. E. Acetone-linked peptides: a convergent approach for peptide macrocyclization and labeling. Angew. Chem. Int. Ed. 54, 8665-8668 (2015).
21. Wang, Y. & Chou, D. H.-C. A thiol-ene coupling approach to native peptide stapling and macrocyclization. Angew. Chem. Int. Ed. 54, 10931-10934 (2015).
22. Lau, Y. H., Andrade, P., de McKenzie, G. J., Venkitaraman, A. R. & Spring, D. R. Linear aliphatic dialkynes as alternative linkers for double-click stapling of p53-derived peptides. ChemBioChem. 15, 2680-2683 (2014).
23. Lau, Y. H. et al. Double strain-promoted macrocyclization for the rapid selection of cell-active stapled peptides. Angew. Chem. Int. Ed. 54, 15410-15413 (2015).
24. Mendive-Tapia, L. et al. New peptide architectures through C-H activation stapling between tryptophan-phenylalanine/tyrosine residues. Nat. Commun. 6, 7160 (2015).
25. Lau, Y. H., Andrade, P., de Wu, Y. & Spring, D. R. Peptide stapling techniques based on different macrocyclisation chemistries. Chem. Soc. Rev. 44, 91-102 (2015).
26. Baek, S. et al. Structure of the stapled p53 peptide bound to Mdm2. J. Am. Chem. Soc. 134, 103-106 (2012).
27. Phillips, C. et al. Design and structure of stapled peptides binding to estrogen receptors. J. Am. Chem. Soc. 133, 9696-9699 (2011).
28. Glas, A. et al. Constrained peptides with target-adapted cross-links as inhibitors of a pathogenic protein-protein interaction. Angew. Chem. Int. Ed. 53, 2489-2493 (2014).
29. Pérez de Vega, M. J., García-Aranda, M. I. & González-Muñiz, R. A role for ring-closing metathesis in medicinal chemistry: mimicking secondary architectures in bioactive peptides. Med. Res. Rev. 31, 677-715 (2011).
30. Wang, D., Chen, K., Kulp, J. L. & Arora, P. S. Evaluation of biologically relevant short alpha-helices stabilized by a main-chain hydrogen-bond surrogate. J. Am. Chem. Soc. 128, 9248-9256 (2006).
31. Mahon, A. B. & Arora, P. S. End-capped α-helices as modulators of protein function. Drug Discov. Today Technol. 9, e57-e62 (2012).
32. Cromm, P. M., Spiegel, J. & Grossmann, T. N. Hydrocarbon stapled peptides as modulators of biological function. ACS Chem. Biol. 10, 1362-1375 (2015).
33. Kim, Y.-W., Grossmann, T. N. & Verdine, G. L. Synthesis of all-hydrocarbon Stapled α-helical peptides by ring-closing olefin metathesis. Nat. Protoc. 6, 761-771 (2011).
34. Blackwell, H. E. & Grubbs, R. H. Highly efficient synthesis of covalently crosslinked peptide helices by ring-closing metathesis. Angew. Chem. Int. Ed. 37, 3281-3284 (1998).
35. Schafmeister, C. E., Po, J. & Verdine, G. L. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122, 5891-5892 (2000).
36. Ghalit, N., Rijkers, D. T. S., Kemmink, J., Versluis, C. & Liskamp, R. M. J. Preorganization induced synthesis of a crossed alkene-bridged nisin Z DE-ring mimic by ring-closing metathesis. Chem. Commun. 192-194 (2005).
37. Slootweg, J. C., Kemmink, J., Liskamp, R. M. J. & Rijkers, D. T. Synthesis and structural characterization of the individual diastereoisomers of a cross-stapled alkene-bridged nisin DE-ring mimic. Org. Biomol. Chem. 11, 7486-7496 (2013).
38. Bird, G. H. et al. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc. Natl Acad. Sci. USA 107, 14093-14098 (2010).
39. Robinson, A. J. et al. Regioselective formation of interlocked dicarba bridges in naturally occurring cyclic peptide toxins using olefin metathesis. Chem. Commun. 28, 4293-4295 (2009).
40. Hilinski, G. J. et al. Stitched α-helical peptides via bis ring-closing metathesis. J. Am. Chem. Soc. 136, 12314-12322 (2014).
41. Fürstner, A. Alkyne metathesis on the rise. Angew. Chem. Int. Ed. 52, 2794-2819 (2013).
42. Aguilera, B. et al. Synthesis of diaminosuberic acid derivatives via ring-closing alkyne metathesis. J. Org. Chem. 66, 3584-3589 (2001).
43. Ijsselstijn, M. et al. Ring-closing alkyne metathesis mediated synthesis of cyclic β-turn mimetics. Tetrahedron Lett. 45, 4379-4382 (2004).
44. Ghalit, N., Poot, A. J., Fürstner, A., Rijkers, D. T. S. & Liskamp, R. M. J. Ringclosing alkyne metathesis approach toward the synthesis of alkyne mimics of thioether A-, B-, C-, and DE-ring systems of the lantibiotic nisin Z. Org. Lett. 7, 2961-2964 (2005).
45. Heppekausen, J. et al. Optimized synthesis, structural investigations, ligand tuning and synthetic evaluation of silyloxy-based alkyne metathesis catalysts. Chem. Eur. J. 18, 10281-10299 (2012).
46. Heppekausen, J., Stade, R., Goddard, R. & Fürstner, A. Practical new silyloxybased alkyne metathesis catalysts with optimized activity and selectivity profiles. J. Am. Chem. Soc. 132, 11045-11057 (2010).
47. Burnley, J., Jackson, W. R. & Robinson, A. J. One-pot selective homodimerization/hydrogenation strategy for sequential dicarba bridge formation. J. Org. Chem. 80, 9057-9063 (2015).
48. Wennerberg, K., Rossman, K. L. & Der, C. J. The Ras superfamily at a glance. J. Cell Sci. 118, 843-846 (2005).
49. McCormick, F. KRAS as a therapeutic target. Clin. Cancer Res. 21, 1797-1801 (2015).
50. Spiegel, J., Cromm, P. M., Zimmermann, G., Grossmann, T. N. & Waldmann, H. Small-molecule modulation of Ras signaling. Nat. Chem. Biol. 10, 613-622 (2014).
51. Cromm, P. M., Spiegel, J., Grossmann, T. N. & Waldmann, H. Direct modulation of small GTPase activity and function. Angew. Chem. Int. Ed. 54, 13516-13537 (2015).
52. Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Dragging ras back in the ring. Cancer Cell 25, 272-281 (2014).
53. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013).
54. Agola, J. O. et al. A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition. ACS Chem. Biol. 7, 1095-1108 (2012).
55. Bhuin, T. & Roy, J. K. Rab proteins: the key regulators of intracellular vesicle transport. Exp. Cell Res. 328, 1-19 (2014).
56. Hutagalung, A. H. & Novick, P. J. Role of Rab GTPases in membrane traffic and cell physiology. Physiol. Rev. 91, 119-149 (2011).
57. Recacha, R. et al. Structural basis for recruitment of Rab6-interacting protein 1 to Golgi via a RUN domain. Structure 17, 21-30 (2009).
58. Belokon', Y. N., Tararov, V. I., Maleev, V. I., Savel'eva, T. F. & Ryzhov, M. G. Improved procedures for the synthesis of (S)-2-[N-(N′-benzylprolyl)amino] benzophenone (BPB) and Ni(II) complexes of Schiff's bases derived from BPB and amino acids. Tetrahedron 9, 4249-4252 (1998).
59. Bird, G. H., Crannell, W. C. & Walensky, L. D. Chemical synthesis of hydrocarbon-stapled peptides for protein interaction research and therapeutic targeting. Curr. Protoc. Chem. Biol. 3, 99-117 (2011).
60. Hou, X. et al. A structural basis for Lowe syndrome caused by mutations in the Rab-binding domain of OCRL1. EMBO J. 30, 1659-1670 (2011).
61. Bleimling, N., Alexandrov, K., Goody, R. & Itzen, A. Chaperone-assisted production of active human Rab8A GTPase in Escherichia coli. Protein Expr. Purif. 65, 190-195 (2009).
62. Simon, I., Zerial, M. & Goody, R. S. Kinetics of interaction of Rab5 and Rab7 with nucleotides and magnesium ions. J. Biol. Chem. 271, 20470-20478 (1996).
63. Huang, X. & Aulabaugh, A. Application of fluorescence polarization in HTS assays. Methods Mol. Biol. 565, 127-143 (2009).
64. Motulsky, H. & Christopoulos, A. Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting (Oxford Univ. Press, 2004).